Is BIO a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Sartorius stake and activist pressure, with revenue (ttm) at ~$2.59B (flat YoY). The bear case rests on revenue is not growing (Q2 2026 was down about 0.1% year over year, and analysts expect about $2.57 billion for 2026, slightly below 2025), and the 2026 outlook was cut in the spring, with currency-neutral revenue guided to roughly a 3% decline to modest growth and operating margin trimmed toward 10% to 12%. Analysts covering it are spread from $280.00 to $390.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Revenue is not growing (Q2 2026 was down about 0.1% year over year, and analysts expect about $2.57 billion for 2026, slightly below 2025), and the 2026 outlook was cut in the spring, with currency-neutral revenue guided to roughly a 3% decline to modest growth and operating margin trimmed toward 10% to 12%. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $280.00, -20.8% from the $353.70 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Sartorius stake and activist pressure. Bio-Rad's roughly 28% holding in Sartorius was worth close to its entire market value in mid-2026, so movements in that German stock swing Bio-Rad's book value and sentiment heavily. The most optimistic analyst target on BIO is $390.00, +10.3% from the $353.70 price. That figure is only reachable if this thesis works close to its best case.

Revenue is not growing (Q2 2026 was down about 0.1% year over year, and analysts expect about $2.57 billion for 2026, slightly below 2025), and the 2026 outlook was cut in the spring, with currency-neutral revenue guided to roughly a 3% decline to modest growth and operating margin trimmed toward 10% to 12%. A Middle East conflict reduced first-quarter revenue and remains a headwind for the blood-typing diagnostics business, which drew a meaningful share of the segment from that region. Because the Sartorius stake dwarfs the operating business in value, Bio-Rad's stock and reported results are highly sensitive to that single holding, and reported GAAP earnings can swing to losses on non-cash marks. Instrument demand across life-science tools has been weak, and any activist campaign carries execution and timing uncertainty. Dual-class shares concentrate voting control with the founding family, which can limit outside influence over the pace of change. After an 18% three-month rally, the stock trades above the average of the few analyst targets (about $335) and at about 36 times forward earnings, so a softer Q3 report on November 4 could weigh on it. The most pessimistic published target is $280.00, -20.8% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Bio-Rad Laboratories designs and sells laboratory instruments, consumables, and reagents across two segments.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Sartorius stake and activist pressure) stalling in the reported numbers rather than in the narrative, the risk above (revenue is not growing (Q2 2026 was down about 0.1% year over year, and analysts expect about $2.57 billion for 2026, slightly below 2025), and the 2026 outlook was cut in the spring, with currency-neutral revenue guided to roughly a 3% decline to modest growth and operating margin trimmed toward 10% to 12%) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

It makes and sells laboratory instruments, reagents, and consumables through two segments: Life Science (PCR, protein analysis, genomics, chromatography) and Clinical Diagnostics (blood typing, quality controls, diabetes monitoring, and specialty assays used in routine labs).

Bio-Rad owns roughly 28% of Sartorius, a German bioprocessing company. In mid-2026 that stake was worth on the order of $5 billion, close to Bio-Rad's entire market value at the time. As a result, Bio-Rad's book value and stock sentiment move heavily with Sartorius shares.

In May 2026, activist Elliott Investment Management disclosed stakes in both Bio-Rad and Sartorius, arguing the market undervalues Bio-Rad's operating business and pushing management to improve the share price and unlock value from the Sartorius holding.